D-684-2013 Class III Terminated
FDA drug recall D-684-2013 was initiated by Teva Pharmaceuticals USA, Inc. on Mar 15, 2013 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing The recall status is terminated (terminated Apr 10, 2014). Affected quantity: 36,708 blister packs.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 17, 2013
- Initiation Date
- Mar 15, 2013
- Termination Date
- Apr 10, 2014
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 36,708 blister packs
Product description
Balziva(TM) (norethindrone and ethinyl estradiol tablets, USP) 0.15 mg/0.03 mg, 28 day regimen, Rx only, Barr Laboratories, Inc., Pomona, NY --- NDC 0555-9034-58
Reason for recall
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Distribution pattern
Nationwide distribution. No foreign or government accounts.
Code information
NDC 0555-9034-58, Lot numbers 33802100A, exp 3/2013; 33802266A, exp 3/2013; and 33802832A, exp 8/2013.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-684-2013
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026